Alnylam Pharmace. Stock
Alnylam Pharmace. Stock
Alnylam Pharmace. dominated the market today, gaining €7.65 (5.670%).
With 36 Buy predictions and not a single Sell prediction Alnylam Pharmace. is an absolute favorite of our community.
With a target price of 228 € there is a hugely positive potential of 62.86% for Alnylam Pharmace. compared to the current price of 140.0 €.
Our community identified positive and negative aspects for Alnylam Pharmace. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Alnylam Pharmace. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 5.670% | 4.556% | -0.178% | -23.077% | -20.904% | 21.739% | 85.997% |
| Ironwood Pharmaceuticals | 6.210% | -3.333% | -8.805% | -22.043% | -28.922% | -21.622% | - |
| Sage Therapeutics Inc. | -3.520% | -3.667% | -23.728% | -70.207% | -38.925% | -81.156% | - |
| Novocure Ltd | -0.080% | 15.965% | -1.196% | -77.601% | -7.391% | -92.217% | - |
Comments
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $200.00 price target on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for ALNY provided by MarketBeat